Clinical Trial

PALACE: Cemiplimab Trial According to ctDNA Levels

Study acronym: PALACE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-01.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT06917573
Lead Sponsor Fundación GECP
Conditions Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Thoracic Neoplasms
Enrollment 63 participants
Start Date 2025-07-29
Primary Completion 2031-12-30 (estimated)
Study Completion 2031-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-19